| Symbol | TOVX |
|---|---|
| Name | THERIVA BIOLOGICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | Maryland, 20850, United States |
| Telephone | (734) 332-7800 |
| Fax | — |
| — | |
| Website | https://www.therivabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000894158 |
| Description | Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Additional info from NASDAQ: |
New Form S-8 - Theriva Biologics, Inc. <b>Filed:</b> 2026-08-24 <b>AccNo:</b> 0001104659-26-100340 <b>Size:</b> 238 KB
Read moreTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2026
Read more(30% Negative) THERIVA BIOLOGICS, INC. (TOVX) Reports Q3 2026 Financial Results
Read moreTheriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
Read moreTheriva™ Biologics anuncia que se ha administrado la primera dosis a un paciente en el ensayo clínico VIRAGE2 de Fase IIa, destinado a evaluar una administración más frecuente de VCN-01 (zabilugene almadenorepvec) en pacientes en tratamiento de primera línea con adenocarcinoma ductal pancreático me…
Read moreTheriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Read moreTheriva™ Biologics anuncia que ha obtenido la autorización reglamentaria para llevar a cabo el ensayo clínico de Fase IIa VIRAGE2, destinado a evaluar una administración más frecuente de VCN-01 (zabilugene almadenorepvec) en pacientes en tratamiento de primera línea con adenocarcinoma pancreático d…
Read more(90% Positive) THERIVA BIOLOGICS, INC. (TOVX) Provides Update on diseases for areas of high unmet need
Read moreNew Form DEF 14A - Theriva Biologics, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001104659-26-078859 <b>Size:</b> 5 MB
Read moreNew Form ARS - Theriva Biologics, Inc. <b>Filed:</b> 2026-06-29 <b>AccNo:</b> 0001104659-26-078961 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy i… | Phase1 | Pancreas Cancer, Metastatic | Recruiting | 2026-08-03 | 2027-12-01 | ClinicalTrials.gov |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With … | Phase2 | Pancreatic Adenocarcinoma | Completed | 2023-01-10 | 2025-03-28 | ClinicalTrials.gov |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Phase1 | Pancreatic Cancer | Active_Not_Recruiting | 2022-03-02 | 2038-09-01 | ClinicalTrials.gov |
| NCT05045833 | Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Toler… | Phase1 | Enteritis Caused by Radiation | Completed | 2021-10-18 | 2022-03-21 | ClinicalTrials.gov |
| NCT04815993 | Pharmacokinetics, Safety, and Tolerability of SYN-020 | Phase1 | Enteritis Caused by Radiation (Disorder) | Completed | 2021-03-22 | 2021-09-30 | ClinicalTrials.gov |
| NCT04692181 | SYN-004 Safety and Tolerability in Allo-HCT Subjects | Phase1 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | Active_Not_Recruiting | 2021-02-15 | 2030-09-30 | ClinicalTrials.gov |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck… | Phase1 | Head and Neck Neoplasms | Unknown | 2019-03-20 | 2023-01-31 | ClinicalTrials.gov |
| NCT03763175 | Efficacy and Safety of SYN-010 in IBS-C | Phase2 | Irritable Bowel Syndrome With Constipation | Terminated | 2018-12-24 | 2020-10-09 | ClinicalTrials.gov |
| NCT02493036 | A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects … | Phase2 | Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | 2015-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02563106 | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI | Phase2 | Clostridium Difficile | Completed | 2015-10-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02495623 | A Study of the Effect of SYN-010 on Subjects With IBS-C | Phase2 | Irritable Bowel Syndrome With Constipation (IBS-C) | Completed | 2015-06-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02473640 | A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftria… | Phase1 | Healthy Volunteers With Ileostomy | Completed | 2015-06-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02419001 | A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults… | Phase1 | Healthy Volunteers | Completed | 2015-03-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitab… | Phase1 | Pancreatic Adenocarcinoma | Completed | 2014-01-01 | 2018-09-01 | ClinicalTrials.gov |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine… | Phase1 | Locally Advanced Solid Tumors | Completed | 2014-01-01 | 2020-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Nab-paclitaxel + Gemcitabine | Other | Phase PHASE1 | Pancreas Cancer, Metastatic | RECRUITING | NCT07701486 |
| VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Other | Phase PHASE1 | Pancreas Cancer, Metastatic | RECRUITING | NCT07701486 |
| Nab-paclitaxel + Gemcitabine | Other | Phase PHASE1 | Pancreas Cancer, Metastatic | NOT_YET_RECRUITING | NCT07701486 |
| VCN-01 oncolytic adenovirus (zabilugene almadenorepvec) | Other | Phase PHASE1 | Pancreas Cancer, Metastatic | NOT_YET_RECRUITING | NCT07701486 |
| Abraxane® | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| VCN-01 | Other | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| Placebo | Other | Phase PHASE2 | Clostridium Difficile | COMPLETED | NCT02563106 |
| SYN-004 | Other | Phase PHASE2 | Clostridium Difficile | COMPLETED | NCT02563106 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT02495623 |
| SYN-010 42 mg | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT02495623 |
| SYN-010 21 mg | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT02495623 |
| SYN-010 | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT02493036 |
| Ceftriaxone | Other | Phase PHASE1 | Healthy Volunteers With Ileostomy | COMPLETED | NCT02473640 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteers With Ileostomy | COMPLETED | NCT02473640 |
| SYN-004 | Other | Phase PHASE1 | Healthy Volunteers With Ileostomy | COMPLETED | NCT02473640 |
| Period 2 - Treatment Sequence AC | Drug | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 2 - Treatment Sequence AB | Drug | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 1 - Treatment Sequence AC | Drug | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 1 - Treatment Sequence AB | Drug | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Abraxane® | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Gemcitabine | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| VCN-01 | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Abraxane® | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Gemcitabine | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| VCN-01 | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Abraxane® | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Gemcitabine | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| VCN-01 | Other | Phase PHASE1 | Locally Advanced Solid Tumors | COMPLETED | NCT02045602 |
| Durvalumab | Other | Phase PHASE1 | Head and Neck Neoplasms | UNKNOWN | NCT03799744 |
| VCN-01 | Other | Phase PHASE1 | Head and Neck Neoplasms | UNKNOWN | NCT03799744 |
| Durvalumab | Other | Phase PHASE1 | Head and Neck Neoplasms | UNKNOWN | NCT03799744 |
| VCN-01 | Other | Phase PHASE1 | Head and Neck Neoplasms | UNKNOWN | NCT03799744 |
| SYN-020 Delayed Release Capsule | Other | Phase PHASE1 | Enteritis Caused by Radiation | COMPLETED | NCT05045833 |
| Placebo | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-010 42 mg | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-010 21 mg | Other | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-020 delayed release capsule | Other | Phase PHASE1 | Enteritis Caused by Radiation (Disorder) | COMPLETED | NCT04815993 |
| VCN-01 | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| VCN-01 | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Nab-paclitaxel | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| huCART-meso Cells | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT05057715 |
| VCN-01 | Other | Phase PHASE1 | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT05057715 |
| SYN-004, Ribaxamase or Placebo | Other | Phase PHASE1 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | ACTIVE_NOT_RECRUITING | NCT04692181 |
| VCN-01 | GENETIC | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Gemcitabine | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Nab-paclitaxel | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | COMPLETED | NCT05673811 |
| Abraxane® | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| Gemcitabine | DRUG | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| Durvalumab | BIOLOGICAL | Phase PHASE1 | Head and Neck Neoplasms | UNKNOWN | NCT03799744 |
| VCN-01 | GENETIC | Phase PHASE1 | Pancreatic Adenocarcinoma | COMPLETED | NCT02045589 |
| SYN-020 Delayed Release Capsule | DRUG | Phase PHASE1 | Enteritis Caused by Radiation | COMPLETED | NCT05045833 |
| SYN-020 delayed release capsule | DRUG | Phase PHASE1 | Enteritis Caused by Radiation (Disorder) | COMPLETED | NCT04815993 |
| SYN-004, Ribaxamase or Placebo | BIOLOGICAL | Phase PHASE1 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | ACTIVE_NOT_RECRUITING | NCT04692181 |
| Placebo | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-010 42 mg | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-010 21 mg | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation | TERMINATED | NCT03763175 |
| SYN-010 | DRUG | Phase PHASE2 | Irritable Bowel Syndrome With Constipation (IBS-C) | COMPLETED | NCT02493036 |
| Ceftriaxone | DRUG | Phase PHASE1 | Healthy Volunteers With Ileostomy | COMPLETED | NCT02473640 |
| Esomeprazole | DRUG | Phase PHASE1 | Healthy Volunteers With Ileostomy | COMPLETED | NCT02473640 |
| SYN-004 | DRUG | Phase PHASE2 | Clostridium Difficile | COMPLETED | NCT02563106 |
| Period 2 - Treatment Sequence AC | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 2 - Treatment Sequence AB | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 1 - Treatment Sequence AC | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |
| Period 1 - Treatment Sequence AB | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02419001 |